PARP Inhibitors Market

2019 Analysis and Review of PARP Inhibitors Market by Drug - Olaparib, Niraparib, Rucaparib, and Talazoparib for 2019-2026

  • 2020-02-12
  • REP-GB-3197
  • 33 Tables
  • 113 Figures
  • 179 pages
  • Format: PDF/PPT/Excel
  • SELECT LICENSE :

  • US$5,000
  • US$7,500
  • US$10,000

PARP Inhibitors Market Size to Expand 4X by 2026

Although the average cancer survival time has doubled in the recent past, a universal cure for cancer is highly unlikely to happen due to complex categorization of the disease as well as uncertainties regarding individual response towards therapies and treatments. To materialize drug development in the field of cancer research, holistic transformation is quintessential. Drug developers are making a concerted effort to implement a multitude of innovations that can spur this transformation to deliver better patient care as well as reach the most vulnerable members of society. As these themes echo the healthcare sector, the poly ADP ribose polymerase (PARP) inhibitors market will experience impressive growth in the coming years. This new FMI study reveals that, global revenue of the PARP inhibitors market is anticipated to surge nearly 4x by 2026.

Frequently Asked Questions about PARP Inhibitors Market

What are the key factors contributing to the growth of the PARP inhibitors market?

Increasing prevalence of advanced stage ovarian cancer, breast cancer, and prostate cancer, and increasing regional product approvals of PARP inhibitors are some of the key factors boosting the growth of the PARP inhibitors market.

How does cost associated with PARP inhibitors affect market growth in emerging economies?

PARP inhibitors have showed significant efficacy in the treatment of cancers as compared to other available traditional platinum chemotherapy. Higher cost associated with PARP inhibitors is expected to hamper their adoption among cancer patients in emerging economies, where reimbursement is not as effective as in developed countries.

What are the leading trends assisting the growth of the PARP inhibitors market?

Launch of new PARP inhibitors through collaborative efforts among key market players in order to expand their regional product offerings, evaluation of various PARP inhibitors for treatment of various cancers, and acquisitions & mergers among clinical phase pharmaceutical and big pharmaceutical companies are some of the key trends shaping the market landscape.

Which type of PARP inhibitor has remarkable growth potential during the forecast period?

Olaparib is expected to be the highest revenue generating product in the PARP inhibitors market, followed by Niraparib. With significant uptake of Olaparib in advanced first-line settings, it is expected to be the bestseller during the forecast period.

Which region is expected to offer significant growth opportunities for the PARP inhibitors market?

North America is estimated to remain the most profitable region in the global PARP inhibitors market during the forecast period, followed by Europe. East Asia is also expected to increase the uptake of PARP inhibitors with various recent and nearing product launches in countries such as China and Japan.

How is the competition scenario in the PARP inhibitors market?

The PARP inhibitors market is expected to be a consolidated market, with major players such as AstraZeneca, GlaxoSmithKline, and Merck Co. & Inc. generating a large chunk of revenue. Through various collaborative efforts with regional players, these big players are expected to enhance their regional presence in the global PARP inhibitors market.

Olaparib Drugs Continue to Capture Leading Market Share

By capturing over ¾ of overall revenue value, Olaparib would remain the preferable drug in the PARP inhibitors market. Moreover, Olaparib has received regulatory approval in a majority of regions. Influenced by the rising cancer patient pool, governments all over the world are giving a green signal to novel anti-cancer drugs such as Niraparib and Talazoparib. Although these new drugs are still yet to receive government consent in some developing regions, their rapid uptake is driving huge attention of market players.

Developed Regions Lead; Developing Regions to Close In

North America and Europe would remain center stage, collectively accounting for a voluminous share of the PARP inhibitors market stack. Strong presence of technology natives as well as conducive reimbursement policies are critical in underpinning market growth in these developed regions. In a bid to address the ever-increasing patient pool, governments in East and South Asia are upping per capita healthcare expenditure. This is influencing stakeholders to view these developing regions for value-creation opportunities.

Expanding Network of Collaborators for Early Identification

Market players must build collaborations with research & academic institutes, digital start-ups, as well as governmental and non-governmental organizations to provide umpteen patient experience and centralize access to physical and virtual care. For instance, Public Health England has launched the 'Be Clear on Cancer' campaign that aims at improving early cancer diagnostics by raising public awareness. Moreover, collaborative efforts such as Cancer MoonShot 2020 are providing researchers with the necessary testing material to develop innovative approaches for treating various oncological disorders.

Olaparib accounts for voluminous share

Niraparib to gain momentum

Ovarian cancer holds leading market share

Prostate cancer to showcase noteworthy CAGR

Retail pharmacies stay ahead with higher share

Distribution via hospital pharmacies on rise

How Growth will Unfold

Around half of the revenue of the PARP inhibitors market would be realized by retail pharmacies, with the number likely to increase at a dexterous pace through 2026. Market players would achieve net earnings worth over US$ 4 Bn via retail pharmacies by the end of forecast period. They are also targeting hospital pharmacies to maximize their profits in the global landscape. This study further emphasizes the avenues of growth and profitability from online pharmacies in the PARP inhibitors market.

PARP Inhibitors Market by Distribution Channel

* This data is only a representation. Actual data may vary and will be available in report.

Click Here To Know How The Growth Will Unfold

Custom Market Research Services

FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Overview

PARP Inhibitors Market Analysis 2019-2026

A recent market study published by Future Market Insights (FMI) offers global industry analysis of 2015-2018 and forecast for 2019-2026. The study also offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the PARP inhibitors market, the growth prospects of the market are obtained with maximum precision.

PARP Inhibitors Market Taxonomy

The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib

Indication

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa

What's Included

The report commences with the executive summary of the PARP inhibitors market, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the PARP inhibitors market.

Readers can find the detailed segmentation and the definition of the PARP inhibitors market in this chapter, which will help them understand the basic information about the PARP inhibitors market. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the PARP inhibitors market report.

The PARP inhibitors market report provides the key market trends that are expected to significantly impact the market growth during the forecast period. Detailed industry trends are provided in this section.

This section includes the factors that have emerged as key successful factors and the strategies adopted by key market participants. It also highlights, pipeline assessment, estimated product launches, regulatory & reimbursement scenario, which are likely to contribute to market growth.

This section explains the global market value analysis and forecast for the PARP inhibitors market during the forecast period. This chapter includes a detailed analysis of the historical PARP inhibitors market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019-2026).

This chapter explains the key macroeconomic factors that are expected to influence the growth of the PARP inhibitors market during the forecast period. Along with the macroeconomic factors, this section also highlights the impact factors, forecast factors, Porter’s five forces analysis for the PARP inhibitors market. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section. Moreover, readers will understand the key trends followed by the leading manufacturers in the PARP inhibitors market.

Based on drug, the PARP inhibitors market is segmented into olaparib, niraparib, rucaparib, and talazoparib. Readers can find information about the key trends and developments in the PARP inhibitors market and market attractiveness analysis based on drug type.

Based on indication, the PARP inhibitors market is segmented into ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. In this chapter, readers can find information about the key trends and developments in the PARP inhibitors market and market attractiveness analysis based on indication for PARP inhibitors.

This chapter provides details about the PARP inhibitors market on the basis of distribution channel, and has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.

This chapter explains how the PARP inhibitors market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).

This chapter includes a detailed analysis of the growth of the North America, along with a country-wise assessment that includes the U.S. and Canada.

Readers can find detailed information about several factors which are impacting the growth of the PARP inhibitors market in Latin America. This chapter also includes the growth prospects of the PARP inhibitors market in the leading LATAM countries such as Brazil, Mexico, and the Rest of Latin America.

Important growth prospects of the PARP inhibitors market based on its end users in several countries such as Germany, the U.K., France, Spain, Italy, and the Rest of Europe, are included in this chapter.

India & Thailand are among the leading countries in the South Asia region, which are the prime subjects of assessment to obtain the growth prospects of the South Asia PARP inhibitors market in this chapter. Readers can find detailed information about the growth parameters of the South Asia PARP Inhibitors market during 2019-2026.

This chapter highlights the growth of the PARP inhibitors market in East Asia by focusing on China, Japan, and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the PARP inhibitors market in East Asia.

In this chapter, Australia and New Zealand are among the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania PARP inhibitors market.

This chapter provides information about how the PARP inhibitors market will grow in the major countries in the MEA region such as GCC Countries, South Africa, Turkey, and the rest of MEA, during the forecast period.

In this chapter, readers can find detailed information about the tier analysis and market concentration of the key players in the PARP inhibitors market, along with their market presence analysis by region and product portfolio.

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the PARP inhibitors market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are AstraZeneca and GlaxoSmithKline plc., Merck Co. & Inc., Clovis Oncology, Pfizer Inc., etc.

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the PARP inhibitors market report.

This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the PARP inhibitors market.

How the research was conducted?

Primary Research

  • C - Level Executives
  • Marketing Directors
  • Sales Heads
  • Portfolio Managers
  • Purchasing Managers
  • Medical Officers
  • Device Development Heads
  • Strategy Advisors
  • R&D Managers
  • Product Manufacturers
  • Distributors
  • Component Suppliers / OEMs
  • Purchasing Departments
  • Physicians / Nursing Managers
  • Industry Experts
  • Current Market Dynamics and Challenges
  • Market Characteristics
  • Market Performance and Growth Quadrants
  • Competition Structure and Market Structure
  • Strategic Growth Initiatives
  • Product Adoption, utilization rate, substitutes
  • Regulatory Landscape
  • Products in Pipeline and Clinical Development
  • Near-term and Long-term Market Growth Prospects
  • Market Segment Splits and Authenticity
  • Opinions on Market Projections and Validity of Assumptions

Secondary Research

  • Industry Magazines 
  • Factiva
  • Organisation for Economic Co-operation and Development
  • Emergency Care Research Institute
  • Global Clinical research Organizations 
  • Research organisations 
  • Company Press Releases
  • Annual Reports and Investor Presentations
  • Peer-reviewed Journals
  • Government Websites and Publications
  • Trade Websites
  • Clinical Trial Registries
  • Country-specific Regulatory Authorities
  • World Bank, WHO, ASCO

Primary Interview Splits

Primary Interview Splits parp inhibitors market designation

Primary Interview Splits parp inhibitors market stakeholders

To Learn More About our Comprehensive Perspective on PARP Inhibitors Market,

Get in touch

Harish Tiwari

Global Head - Business Development

Akshay Godge

Client Partner - Global Business Development

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Methodology